KPTI earnings call for the period ending March 31, 2019.
News & Analysis: Karyopharm Therapeutics
Investors were pleased with the company's latest presentation.
An FDA delay was seen as good news for the drugmaker.
KPTI earnings call for the period ending December 31, 2018.
It looks like an upcoming FDA advisory committee meeting will be an uncomfortable affair for this clinical-stage biotech.
This clinical-stage company reported significant news yesterday.
It wasn't easy to do in the midst of a market meltdown, but these biotech stocks generated strong gains this week.
It was an exciting month of ups and downs for the biotech and its blood-cancer candidate.
Shares dropped after the biotech reported news from an important phase 2 clinical trial.
Novavax, Agile Therapeutics, and Karyopharm Therapeutics are about to release registration-ready trial data.